CB-839, a potent reversible noncompetitive allosteric GLS inhibitor, in combination with erlotinib for EGFR-mutated non-small cell lung cancer, inhibits tumor growth by impairing both glucose and Gln utilization (25). The gene discussed is GLS; the disease is neoplasm.